As the world’s leading, and only forum committed to overcoming significant R&D hurdles, and sharing best practices for next generation therapies for chronic inflammatory and autoimmune dermatological conditions. The 5th annual meeting addresses advances and challenges in genetic discoveries, antibody drug development, delivery strategies and predictive and diagnostic technologies when developing drugs for moderate-to-severe inflammatory skin conditions.

We are delighted to announce that SCARLETRED is an innovation partner for the first time of the renowned congress. As part of the summit, our CEO, Dr. Harald Schnidar, will be among the speakers and will provide unique insights into “Artificial Intelligence Supported Skin Drug Testing & Applications in Post Marketing”, focusing on mobile skin imaging and analysis, evaluating automated data management and machine learning as well as examine patient reported outcome and real world evidence.

‍

Visit the official homepage of the 5th Annual Dermatology Drug Development Summit to explore more about the event.